Prelude Therapeutics Return on Equity

Prelude Therapeutics (PRLD) currently reports a ROE of -45.23%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Prelude Therapeutics's ROE history and peer comparisons.

Prelude Therapeutics's ROE of -45.23% is lower than the Healthcare sector average of 20.86%. That is roughly 316.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Prelude Therapeutics's current -45.23% should be judged against Healthcare norms (sector average: 20.86%) and against PRLD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -45.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Prelude Therapeutics, and consider following PRLD for alerts when major investors trade the stock.

Prelude Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -45.23% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRLD with unrelated industries.